Talquetamab for Patients With Relapsed/Refractory MM

Opinion
Video

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Recent Videos
3 experts in this video
3 experts in this video
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
3 experts in this video
3 experts in this video
2 experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this video
Related Content